Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck’s blockbuster Keytruda.

Previous post ‘I’ve never invested in the stock market’: I’m 64 with $400,000 in CDs and a high-yield savings account. Should I invest in bonds?
Next post KeyCorp to book $700 million loss on sale of securities